MADONNA UGBOR: Open Payments
NPI 1124423256 · BOWIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,183 in 106 payments from 11 companies in 2025. Trend: 2023 $1,781 · 2024 $1,864 · 2025 $3,183
Food & beverage: $3,172Education: $12
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $571 |
| Alkermes, Inc. | 16 | $465 |
| Lundbeck LLC | 22 | $447 |
| E.R. Squibb & Sons, L.L.C. | 8 | $342 |
| Vanda Pharmaceuticals Inc. | 10 | $316 |
| Janssen Pharmaceuticals, Inc | 6 | $304 |
| Neurocrine BioSciences, Inc. | 7 | $259 |
| Otsuka America Pharmaceutical, Inc. | 6 | $217 |
| Teva Pharmaceuticals USA, Inc. | 9 | $203 |
| ABBVIE INC. | 2 | $43 |
Products named: CAPLYTA, ABILIFY ASIMTUFII, ARISTADA, COBENFY, INVEGA SUSTENNA, INGREZZA, FANAPT, HETLIOZ.
Industry payments across MD — which companies pay providers there.
